How have SAVAW shares performed in 2024?

Cassava Sciences' stock was trading at $7.01 at the beginning of 2024. Since then, SAVAW stock has decreased by 99.6% and is now trading at $0.03. View the best growth stocks for 2024 here .

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Cassava Sciences?

Shares of SAVAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SAVAW

Cassava Sciences (SAVAW) Stock Price, News & Analysis

→ The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad)

Free SAVAW Stock Alerts

$0.03

0.00 (0.00%)

(As of 05/6/2024)

Compare

Today's Range: $0.03
▼
$0.03
50-Day Range: $0.03
▼
$6.58
52-Week Range: $0.02
▼
$11.02

Volume: N/A
Average Volume: 474,310 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get Cassava Sciences alerts:

Ad InvestorPlace

Crypto Pioneer Says: “The last crypto bull market has begun.”

Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.

Click here if you’d like to learn more about these five cryptos…

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

SAVAW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SAVAW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive SAVAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:SAVAW
CUSIP: N/A
CIK: 1069530
Web: www.cassavasciences.com
Phone: 512-501-2444
Fax: N/A
Employees: 29
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: No Data
Beta: N/A

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Remi Barbier (Age 64)
Founder, Chairman, President & CEO
Comp: $1.2M
Mr. Eric J. Schoen (Age 56)
Chief Financial Officer
Comp: $460k
Mr. R. Christopher Cook (Age 60)
Senior VP, Company Secretary & General Counsel
Comp: $425k
Dr. James W. Kupiec M.D. (Age 71)
Chief Medical Officer
Comp: $435k
Dr. George Thornton Ph.D.
Senior Vice President of Technology
Mr. Michael Zamloot
Senior Vice President of Technical Operations
Dr. Michael Marsman Pharm.D.
Senior Vice President of Regulatory Affairs
Dr. Lindsay H. Burns Ph.D.
Senior Vice President of Neuroscience

Key Competitors

View All Competitors

Institutional Ownership

Walleye Trading LLC
Bought 41,900 shares on 5/17/2024
Ownership: 0.000%

View All Institutional Transactions

SAVAW Stock Analysis - Frequently Asked Questions

How have SAVAW shares performed in 2024?: Cassava Sciences' stock was trading at $7.01 at the beginning of 2024. Since then, SAVAW stock has decreased by 99.6% and is now trading at $0.03.
View the best growth stocks for 2024 here.
Who are Cassava Sciences' major shareholders?: Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Cassava Sciences?: Shares of SAVAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAVAW) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial